Evaluation of alpha defensin, IL-1 receptor antagonist, and IL-18 levels in COVID-19 patients with macrophage activation syndrome and acute respiratory distress syndrome.
COVID-19
IL-18
IL-1Ra
alpha defensin
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
12
08
2020
revised:
22
09
2020
accepted:
07
10
2020
pubmed:
11
10
2020
medline:
6
3
2021
entrez:
10
10
2020
Statut:
ppublish
Résumé
Many laboratory parameters have been associated with morbidity and mortality in SARS-CoV-2 (COVID-19), which emerged in an animal market in Wuhan, China in December 2019 and has infected over 20 million people. This study investigated the relationship between serum interleukin (IL)-18, IL-1 receptor antagonist (IL-1Ra), and alpha defensin levels and the clinical course and prognosis of COVID-19. This study included 100 patients who were admitted to the chest diseases department and intensive care unit of our hospital and diagnosed with COVID-19 by real-time polymerase chain reaction (PCR) of nasopharyngeal swab samples between March 24 and May 31, 2020. The control group consisted of 50 nonsymptomatic health workers with negative real-time PCR results in routine COVID-19 screening in our hospital. Serum alpha defensin, IL-1Ra, and IL-18 levels were significantly higher in patients who developed macrophage activation syndrome (MAS) and acute respiratory distress syndrome (ARDS) compared to patients who did not (p < .001 for all). Alpha defensin, IL-1Ra, and IL-18 levels were significantly higher in COVID-19 patients with and without MAS or ARDS when compared to the control group (p < .001 for all). When the 9 patients who died were compared with the 91 surviving patients, IL-1Ra and IL-18 levels were found to be significantly higher in the nonsurvivors (p < .001). Our findings of correlations between alpha defensin and levels of IL-1Ra and IL-18, which were previously shown to be useful in COVID-19 treatment and follow-up, indicates that it may also be promising in treatment.
Sections du résumé
BACKGROUND
Many laboratory parameters have been associated with morbidity and mortality in SARS-CoV-2 (COVID-19), which emerged in an animal market in Wuhan, China in December 2019 and has infected over 20 million people. This study investigated the relationship between serum interleukin (IL)-18, IL-1 receptor antagonist (IL-1Ra), and alpha defensin levels and the clinical course and prognosis of COVID-19.
MATERIALS AND METHODS
This study included 100 patients who were admitted to the chest diseases department and intensive care unit of our hospital and diagnosed with COVID-19 by real-time polymerase chain reaction (PCR) of nasopharyngeal swab samples between March 24 and May 31, 2020. The control group consisted of 50 nonsymptomatic health workers with negative real-time PCR results in routine COVID-19 screening in our hospital.
RESULTS
Serum alpha defensin, IL-1Ra, and IL-18 levels were significantly higher in patients who developed macrophage activation syndrome (MAS) and acute respiratory distress syndrome (ARDS) compared to patients who did not (p < .001 for all). Alpha defensin, IL-1Ra, and IL-18 levels were significantly higher in COVID-19 patients with and without MAS or ARDS when compared to the control group (p < .001 for all). When the 9 patients who died were compared with the 91 surviving patients, IL-1Ra and IL-18 levels were found to be significantly higher in the nonsurvivors (p < .001).
CONCLUSION
Our findings of correlations between alpha defensin and levels of IL-1Ra and IL-18, which were previously shown to be useful in COVID-19 treatment and follow-up, indicates that it may also be promising in treatment.
Identifiants
pubmed: 33038012
doi: 10.1002/jmv.26589
pmc: PMC7675303
doi:
Substances chimiques
IL18 protein, human
0
Interleukin 1 Receptor Antagonist Protein
0
Interleukin-18
0
alpha-Defensins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2090-2098Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Arthritis Rheumatol. 2020 Jul;72(7):1059-1063
pubmed: 32293098
Indian J Pediatr. 2020 Apr;87(4):281-286
pubmed: 32166607
PLoS Pathog. 2017 Jun 16;13(6):e1006446
pubmed: 28622386
Nat Rev Immunol. 2020 May;20(5):277
pubmed: 32249847
Respirology. 2005 Jun;10(3):295-9
pubmed: 15955140
J Mol Biol. 2013 Dec 13;425(24):4965-80
pubmed: 24095897
Annu Rev Virol. 2017 Sep 29;4(1):369-391
pubmed: 28715972
Nat Rev Immunol. 2020 May;20(5):269-270
pubmed: 32273594
J Acquir Immune Defic Syndr. 2004 Apr 15;35(5):455-63
pubmed: 15021310
Nat Biotechnol. 2020 Aug;38(8):970-979
pubmed: 32591762
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
J Infect Dis. 2007 Sep 15;196(6):835-43
pubmed: 17703413
Immunol Rev. 2008 Jun;223:20-38
pubmed: 18613828
J Med Virol. 2021 Apr;93(4):2090-2098
pubmed: 33038012
Lancet. 2020 Mar 7;395(10226):809-815
pubmed: 32151335
J Immunol. 2007 Jun 15;178(12):8046-52
pubmed: 17548642
Autoimmun Rev. 2020 Jun;19(6):102537
pubmed: 32251717
Eur Cytokine Netw. 2006 Dec;17(4):224-52
pubmed: 17353157
Lancet Respir Med. 2020 Jun;8(6):544-546
pubmed: 32380023
JAMA. 2020 May 12;323(18):1824-1836
pubmed: 32282022
J Mol Med (Berl). 2005 Aug;83(8):587-95
pubmed: 15821901